e-Therapeutics expands its global footprint in China
Two companies specialised in drug discovery and development have formed a partnership to evaluate the effectiveness of molecules in the area oncology.
e-Therapeutics is collaborating with the Nanjing KeyGen Biotech Company in China, on the effectiveness of specific molecules.
The initial focus of the collaboration will be to combine the respective capabilities and expertise of both companies in the evaluation of specific molecules that may have a therapeutic application in oncology.
As the relationship develops, the partnership will combine e-Therapeutics’ systems biology drug discovery and drug evaluation platform, with KeyGen’s cell-based assays and preclinical capabilities. KeyGen is a subsidiary of Nanjing Medical Group.
e-Therapeutics has proprietary complex systems analysis tools which enable the assessment and the discovery of drug candidates with desirable properties in efficacy, safety and tolerance, while KeyGen’s high-level cell-culture facilities and substantial expertise in anti-cancer drugs will allow pre-clinical testing of the oncology candidates that e-Therapeutics finds.
Any exploitation of potential drug candidates and further work between the two companies will be the subject of further agreement which, if entered into, would be announced in due course.
e-Therapeutics’ ceo Professor Malcolm Young said: ‘This marks a significant partnership for us in Asia and we are delighted to be collaborating with one of China’s leading biotechnology companies. We believe KeyGen’s relationship with Nanjing Medical Group, which is a top pharmaceutical group in China, provides us with direct access to some of China’s most eminent scientists and doctors, in addition to a well established market presence. We hope that this strong research and development partnership will lead to the development of promising, new oncology drugs.’
KeyGen’s ceo Dr Wanzhou Zhao, said: ‘KeyGen is delighted to be collaborating with, what we believe is one of the West’s fastest growing biotechnology companies. In our opinion, e-Therapeutics possesses a unique platform for addressing the principal risks in drug discovery and development. We are very excited about working with e-Therapeutics to develop new and effective cancer therapies.’